Resolution Therapeutics Strengthens Leadership Team with Key Executive Appointments as RTX001 Advances in Clinical Trials
Key Insights
Resolution Therapeutics (search) appointed Lucy Singah as Chief Financial Officer and Daniel Kennedy as Chief Business Officer following the successful first patient dosing in its Phase I/II EMERALD study.
Singah brings over 20 years of corporate finance experience including roles at GSK and multiple successful fundraising rounds across biotech companies.
Kennedy contributes over 20 years of business development expertise, having previously led deals at Immunocore (search) and Achillion Pharmaceuticals (search) prior to its $930 million acquisition by Alexion.
Resolution Therapeutics (search), a clinical-stage biopharmaceutical company pioneering regenerative macrophage therapies, has appointed two senior executives to strengthen its leadership team as the company advances its lead therapeutic candidate RTX001 through clinical development. The Edinburgh and London-based company announced the appointments of Lucy Singah as Chief Financial Officer and Daniel Kennedy as Chief Business Officer on September 10, 2025.
The leadership additions follow Resolution's recent milestone of successfully dosing the first patient with RTX001 in its Phase I/II EMERALD study, marking a critical advancement for the company's novel approach to treating inflammatory and fibrotic diseases (search).
Executive Appointments Drive Strategic Growth
Lucy Singah joins Resolution with over 20 years of corporate and strategic finance experience spanning both UK and US start-ups and global pharmaceutical companies. Most recently serving as Chief Financial Officer at Echopoint Medical, Singah led financial planning, payment system implementation, and board-level support during key development stages. Her extensive background includes overseeing multiple successful fundraising rounds at Amazonia Impact Ventures and Axis Spine Technologies, as well as 11 years at GSK in various roles including M&A, Investor Relations, and finance leadership in Procurement and Consumer Healthcare.
"I am honoured to join Resolution at such a pivotal stage in the Company's development," said Singah. "I look forward to collaborating with the team and leveraging my experience to advance the Company's financial goals and drive RTX001 through the clinic."
Daniel Kennedy brings over 20 years of business development expertise to his new role as Chief Business Officer. His track record includes serving as Vice President of Business Development at Immunocore (search) plc (NASDAQ: IMCR) and leading business development and alliance management at Achillion Pharmaceuticals (search) prior to its acquisition by Alexion Pharmaceuticals (NASDAQ: ALXN) for $930 million in cash plus up to $300 million in contingent value rights. Kennedy has also held positions at Schering-Plough and GSK, where he managed diverse responsibilities spanning business development transactions for R&D, alliance management, global corporate development, and commercial operations.
RTX001 Advances in Clinical Development
The executive appointments coincide with significant progress in Resolution's clinical program. RTX001, the company's lead product candidate, is an engineered autologous regenerative macrophage therapy with enhanced anti-fibrotic and anti-inflammatory effects. The therapy is engineered with IL-10-MMP9 (search) mRNA to enhance the natural regenerative properties of macrophages for superior efficacy and durability.
The EMERALD Phase I/II study represents a first-in-human, open-label clinical trial in end-stage liver disease (search), with clinical events serving as the primary efficacy endpoint. The study is currently recruiting patients and has successfully cleared safety requirements for the first patient dosing.
Dr. Amir Hefni, Chief Executive Officer of Resolution Therapeutics (search), emphasized the strategic timing of these appointments: "We are delighted to welcome Lucy and Dan to our leadership team at this exciting time in the Company's journey, having recently announced the successful dosing of the first patient with RTX001. I look forward to working with the strengthened executive team to deliver on our vision to transform patient outcomes by pioneering regenerative macrophage therapy (RMT) in inflammatory and fibrotic diseases (search)."
Platform Expansion Beyond Liver Disease
Resolution's proprietary platform extends beyond its initial focus on end-stage liver disease (search). The company is advancing efforts to expand the potential of its regenerative macrophage therapy platform into additional inflammatory and fibrotic indications, including graft-vs-host disease (search) (GVHD) and lung fibrosis (search).
The company, which originated as a spinout from Professor Stuart Forbes's lab at the University of Edinburgh, has positioned itself to leverage preclinical data demonstrating anti-fibrotic and anti-inflammatory advantages of its engineered macrophages relative to non-engineered alternatives.
Resolution is scheduled to host an R&D Webinar on September 17, 2025, at 2pm BST alongside world-leading clinical hepatologists, providing additional insights into the company's therapeutic approach and clinical development strategy.